Sunday, April 18, 2021

Latest:

BCM Docappella performs virtual cover of “Sucker”
Selecting the right deconvolution method just got easier
New clinic provides care, support for patients managing COVID-19 at home
Clinical trial sets out to improve prognosis for pancreatic cancer patients
Closer to human – mouse model more accurately reproduces fatty liver disease

Baylor College of Medicine Blog Network

Blog Network
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
- About Progress Notes
- Connect With Us
bcm.edu

CDK4/6 inhibitor therapy

From The Labs

Interferon linked to ER+/HER- metastatic breast cancer resistance to therapy

March 12, 2021March 12, 2021 Ana Rodríguez 0 Comments CDK4/6 inhibitor therapy, endocrine therapy, ER+/HER2- breast cancer, Interferon, Metastatic breast cancer, Research, resistance to cancr treatment

Both preclinical models and tumor samples from patients with ER+/HER2- breast cancer link high IFN signaling to resistance to treatment.

From the Labs features an image of early physical training of Rett mice, which results in the development of more dendritic arbors or cellular projections in a task-specific group of neurons in the hippocampus (red). Image credit: N.P. Achilly/Zoghbi lab/Nature, 2021.